Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of Bintrafusp alfa (M7824) in Solid Tumors
2021-000179-36Phase 3Active
- Sponsor
- Merck KGaA
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bintrafusp alfa in non-small cell lung cancer (NSCLC), biliary cancer, Cervical Cancer (CC) and 1 more, sponsored by Merck KGaA. Primary endpoint: Occurrence of AEs and treatment-related AEs. Started Aug 2021; status: active.
02
Drugs
bintrafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)biliary cancerCervical Cancer (CC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2021-000179-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000179-36.